TABLE 2

Baseline measurementsa

ParameterMean value ± SD
Effect of challenge with vasopressin (AVP)Effect of ET challenge with constant pressureEffect of Raxi with ET challengeEffect of adefovir with ET challengeEffect of ET challenge with constant flow
DiluentAVPPAETET + NS-AbET + RaxiET + diluentET + adefovirPAET
Flow (ml/min)32.8 ± 1.031.4 ± 0.929.3 ± 1.327.5 ± 0.833.1 ± 1.736.1 ± 1.630.8 ± 0.730.8 ± 0.929.5 ± 0.930.4 ± 0.6
Perfusion pressure (mm Hg)101.8 ± 1.4100.7 ± 0.999.9 ± 0.9100.8 ± 0.898.8 ± 0.597.7 ± 1.0100.9 ± 1.0101.8 ± 1.0101.1 ± 1.6100.9 ± 1.6
GFR (ml/min)0.83 ± 0.030.88 ± 0.050.71 ± 0.050.77 ± 0.060.77 ± 0.040.83 ± 0.040.75 ± 0.030.79 ± 0.040.75 ± 0.030.77 ± 0.03
Fractional free water reabsorption0.81 ± 0.010.81 ± 0.010.88 ± 0.010.88 ± 0.010.83 ± 0.010.84 ± 0.010.84 ± 0.010.84 ± 0.010.84 ± 0.010.83 ± 0.02
Urine output (μl/min)157.2 ± 10.9168.1 ± 11.186.6 ± 8.495.4 ± 10.5132.8 ± 13.9135.7 ± 11.0123.5 ± 7.8125.7 ± 9.6126 ± 15130 ± 15
Fractional sodium reabsorption0.82 ± 0.010.81 ± 0.010.88 ± 0.010.88 ± 0.010.83 ± 0.010.84 ± 0.010.84 ± 0.010.85 ± 0.010.84 ± 0.020.84 ± 0.02
  • a Raxi, raxibacumab; NS-Ab, nonspecific antibody.